Blair William & Co. IL cut its stake in shares of Allergan plc (NYSE:AGN) by 13.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 28,693 shares of the company’s stock after selling 4,300 shares during the period. Blair William & Co. IL’s holdings in Allergan were worth $4,829,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Prosight Management LP purchased a new stake in Allergan during the 4th quarter valued at $16,031,000. Tower Research Capital LLC TRC raised its stake in Allergan by 479.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock valued at $289,000 after buying an additional 1,463 shares during the last quarter. Canyon Capital Advisors LLC raised its stake in Allergan by 248.4% during the 4th quarter. Canyon Capital Advisors LLC now owns 501,494 shares of the company’s stock valued at $82,034,000 after buying an additional 357,559 shares during the last quarter. Vantage Financial Partners Ltd. Inc. raised its stake in Allergan by 23.8% during the 4th quarter. Vantage Financial Partners Ltd. Inc. now owns 6,250 shares of the company’s stock valued at $1,018,000 after buying an additional 1,200 shares during the last quarter. Finally, Stephens Inc. AR raised its stake in Allergan by 24.2% during the 1st quarter. Stephens Inc. AR now owns 30,566 shares of the company’s stock valued at $5,144,000 after buying an additional 5,960 shares during the last quarter. Institutional investors and hedge funds own 79.16% of the company’s stock.
AGN has been the subject of a number of research reports. Wells Fargo & Co reiterated a “buy” rating on shares of Allergan in a research note on Tuesday, June 5th. Piper Jaffray Companies set a $161.00 target price on shares of Allergan and gave the company a “hold” rating in a research note on Thursday, May 31st. Vetr lowered shares of Allergan from a “buy” rating to a “hold” rating and set a $171.99 target price for the company. in a research note on Tuesday, April 17th. Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the company a “hold” rating in a research note on Friday, April 27th. Finally, Deutsche Bank set a $210.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Tuesday, May 1st. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $212.15.
Allergan (NYSE:AGN) last issued its earnings results on Monday, April 30th. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $3.36 by $0.38. The company had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.59 billion. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. Allergan’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.35 EPS. sell-side analysts forecast that Allergan plc will post 16.06 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 15th. Investors of record on Friday, May 18th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.66%. The ex-dividend date of this dividend was Thursday, May 17th. Allergan’s dividend payout ratio is currently 17.61%.
In related news, EVP William Meury sold 24,425 shares of the company’s stock in a transaction on Thursday, May 17th. The shares were sold at an average price of $154.59, for a total value of $3,775,860.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.37% of the company’s stock.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.